These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33993168)

  • 1. Opioids in the United Kingdom: safety and surveillance during COVID-19.
    Osborne V
    Curr Opin Psychiatry; 2021 Jul; 34(4):357-362. PubMed ID: 33993168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining treatment and prevention programs for opioid use disorders during the coronavirus disease 2019 pandemic.
    Li R; Zhao M
    Curr Opin Psychiatry; 2021 Jul; 34(4):369-375. PubMed ID: 33859127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
    Alexander K; Pogorzelska-Maziarz M; Gerolamo A; Hassen N; Kelly EL; Rising KL
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):60. PubMed ID: 34372900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine Opioid Treatment During the COVID-19 Pandemic.
    Luigi M; Luo M; Maes EJP
    JAMA Intern Med; 2021 Aug; 181(8):1135. PubMed ID: 33843962
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.
    Nguyen TD; Saloner B; Stein BD
    JAMA Intern Med; 2021 Aug; 181(8):1135-1136. PubMed ID: 33843947
    [No Abstract]   [Full Text] [Related]  

  • 9. Opioid use and misuse in Europe: COVID-19 new challenges?
    Torrens M; Fonseca F
    Eur Neuropsychopharmacol; 2022 Jan; 54():67-69. PubMed ID: 34565653
    [No Abstract]   [Full Text] [Related]  

  • 10. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid prescribing among aged care residents during the first year of the COVID-19 pandemic: an analysis using general practice health records in Australia.
    Dai Z; Raban MZ; Sezgin G; McGuire P; Datta S; Wabe N; Pearce C; Woodman R; Georgiou A
    BMC Geriatr; 2023 Feb; 23(1):111. PubMed ID: 36829128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 13. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging options to combat the opioid epidemic.
    Kominek C
    Am J Manag Care; 2018 May; 24(10 Suppl):S207-S214. PubMed ID: 29851450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.
    Krawczyk N; Bunting AM; Frank D; Arshonsky J; Gu Y; Friedman SR; Bragg MA
    Int J Drug Policy; 2021 Jun; 92():103140. PubMed ID: 33558165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
    Lister JJ; Lister HH
    Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect.
    Manchikanti L; Singh VM; Staats PS; Trescot AM; Prunskis J; Knezevic NN; Soin A; Kaye AD; Atluri S; Boswell MV; Abd-Elsayed A; Hirsch JA
    Pain Physician; 2022 Mar; 25(2):97-124. PubMed ID: 35322965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adolescents and opioid-related outcomes amidst the COVID-19 pandemic.
    Romero RA; Young SD
    J Addict Dis; 2022; 40(1):126-130. PubMed ID: 33955321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.